Health and Functional Status of Adults Aged 90 Years in the United States
From 2010 to 2050, the number of people 90 years or older in the United States is projected to more than quadruple and comprise 10% of the 65 years or older population. 1 There is limited information, however, about the health and functional status of such individuals. The Cardiovascular Health Study (CHS), which began in 1989, is a federally funded observational community-based study of risk factors for cardiovascular disease in people 65 years and older. The healthy participant bias in the study has attenuated over time, and retention has remained high throughout followup, even for the oldest participants. 2, 3 We describe the health and functional status of participants at age 90 years.
Methods | The Cardiovascular Health Study is a prospective observational study of 5888 black and white adults 65 years or older recruited in 2 waves (1989-1990 and 1992-1993) 4 We assessed depressive symptoms with a modified
10-item Centers for Epidemiologic Studies Depression (CES-D)
scale, and adjudicated cardiovascular events. 5 Dementia was identified from multiple sources, including the CHS Cognition Study, an ancillary study of participants in which dementia was adjudicated, medications indicated for Alzheimer disease and dementia, and International Classification of Diseases Medical Diagnosis (ICD-9) codes.
Results | Of 5888 CHS participants, 2062 (35.0%) survived to 90 years as of July 16, 2015. There were 1889 (91.6% of those surviving) participants with available measures, and of these, 65.5% were women. Most women (59.0%) and men (62.0%) reported being in good or better health and being without depressive symptoms (76.6% and 77.8%, respectively) at 90 years ( Table 1) . The mean 3MSE scores were close to 80 points; below this level indicates cognitive impairment. Women were taking a mean (SD) of 6.5 (3.9) medications and men were taking 5.7 (3.7); the 5 most common types of drugs were medications for high blood pressure, aspirin, lipid-lowering agents, thyroid medications, and antidepressants. Most women (75.6%) and men (58.7%) reported difficulty walking half a mile, although fewer reported difficulty walking up 10 steps (60.6% and 42.3%, respectively). Most also reported difficulty on 1 or more instrumental activities of daily living, such as preparing food and performing light housework (74.8% and 59.4% for women and men, respectively), and fewer reported difficulty on 1 or more activities of daily living, such as bathing and dressing (52.7% and 37.8%, respectively).
Nearly half of women (47.0%) and men (52.8%) had cardiovascular disease by age 90 years, the most prevalent type was coronary heart disease ( Table 2 ). More men than women had a history of cancer, and more women had dementia. Most (73.0%) participants had 1 or more of the chronic diseases assessed by age 90 years (Table 2) . b P values from Wald tests for heterogeneity of OR by sex.
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Discussion | In the community-based CHS, we found that participants surviving to age 90 years were likely to have a high burden of disability and morbidity, yet report that their health status was good. Consistent with other studies, we found that a greater proportion of disability among women than men, as observed closer to age 65 years, persisted at age 90 years. 6 Notably, at age 90 years participants were taking a mean of 6.2 medications, which may be a consequence of the high prevalence of multiple chronic conditions as well as the availability of medications for many of these conditions. Limitations of our study include the potential for missing data among persons in the worst health, possible reporting bias in the self-reported measures, and limited racial/ethnic diversity. Better understanding of the health and functional status of nonagenarians in the United States should facilitate planning for long-term care services that respond to and accommodate the high burden of morbidity and disability, and improve lives. 
Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016
The epinephrine autoinjector EpiPen received considerable scrutiny in the past year because Mylan, its manufacturer, increased its list price to $609 even though the only ingredient, epinephrine, was discovered over 100 years ago (the delivery system is patented).
Mylan recently announced a $465 million settlement with the Department of Justice (DOJ) to resolve a fraud investigation, 1 alleging that Mylan misclassified EpiPen as a 
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